WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that its scientists are scheduled to make several presentations at the 41st annual meeting of the Society for Neuroscience being held in Washington, D.C. from November 12 through November 16, 2011, as well as at “Nicotinic Acetylcholine Receptors as Therapeutic Targets: Basic Research and Clinical Sciences,” a satellite meeting of the Society for Neuroscience taking place at Hyatt Dulles in Herndon, Virginia from November 9 through November 11, 2011.
